Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Inventory: 2020-2025

Historic Inventory for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $67.5 million.

  • Xeris Biopharma Holdings' Inventory rose 49.52% to $67.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.5 million, marking a year-over-year increase of 49.52%. This contributed to the annual value of $48.2 million for FY2024, which is 24.04% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Inventory stood at $67.5 million, which was up 0.27% from $67.3 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Inventory high stood at $67.5 million for Q3 2025, and its period low was $14.2 million during Q3 2021.
  • In the last 3 years, Xeris Biopharma Holdings' Inventory had a median value of $43.0 million in 2024 and averaged $46.1 million.
  • Data for Xeris Biopharma Holdings' Inventory shows a peak YoY surged of 116.90% (in 2021) over the last 5 years.
  • Xeris Biopharma Holdings' Inventory (Quarterly) stood at $18.1 million in 2021, then skyrocketed by 36.52% to $24.7 million in 2022, then spiked by 57.02% to $38.8 million in 2023, then grew by 24.04% to $48.2 million in 2024, then spiked by 49.52% to $67.5 million in 2025.
  • Its Inventory stands at $67.5 million for Q3 2025, versus $67.3 million for Q2 2025 and $52.7 million for Q1 2025.